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Abstract 
Background: Latent HIV‑1 reservoirs are identified as one of the major challenges to achieve HIV‑1 cure. Currently 
available strategies are associated with wide variability in outcomes both in patients and CD4+ T cell models. This 
underlines the critical need to develop innovative strategies to predict and recognize ways that could result in better 
reactivation and eventual elimination of latent HIV‑1 reservoirs.
Results and discussion: In this study, we combined genome wide transcriptome datasets post activation with Sys‑
tems Biology approach (Signaling and Dynamic Regulatory Events Miner, SDREM analyses) to reconstruct a dynamic 
signaling and regulatory network involved in reactivation mediated by specific activators using a latent cell line. This 
approach identified several critical regulators for each treatment, which were confirmed in follow‑up validation stud‑
ies using small molecule inhibitors. Results indicate that signaling pathways involving JNK and related factors as pre‑
dicted by SDREM are essential for virus reactivation by suberoylanilide hydroxamic acid. ERK1/2 and NF‑κB pathways 
have the foremost role in reactivation with prostratin and TNF‑α, respectively. JAK‑STAT pathway has a central role in 
HIV‑1 transcription. Additional evaluation, using other latent J‑Lat cell clones and primary T cell model, also confirmed 
that many of the cellular factors associated with latency reversing agents are similar, though minor differences are 
identified. JAK‑STAT and NF‑κB related pathways are critical for reversal of HIV‑1 latency in primary resting T cells.
Conclusion: These results validate our combinatorial approach to predict the regulatory cellular factors and path‑
ways responsible for HIV‑1 reactivation in latent HIV‑1 harboring cell line models. JAK‑STAT have a role in reversal of 
latency in all the HIV‑1 latency models tested, including primary CD4+ T cells, with additional cellular pathways such 
as NF‑κB, JNK and ERK 1/2 that may have complementary role in reversal of HIV‑1 latency.
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Background
Development of combined antiretroviral therapy (cART) 
has made it possible to treat and control HIV-1 infec-
tion in infected individuals. Despite these major strides 
in the management of HIV-1 infection, HIV-1 cure still 
remains a challenge. Virus persists indefinitely even when 
the patient is treated with cART. Studies have identified 
resting CD4+ T cells as the main reservoir for the latent 
virus [1–5]. Discontinuation or interruption of treatment 
in well-controlled subjects results in increasing virus 
titer and recurrence of clinical symptoms associated 
with HIV/AIDS. This is due to the ability of the virus to 
establish a state of latent infection in a small number of 
cells where the virus remains transcriptionally silent for 
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long periods of time [6–8]. Currently available antiret-
roviral agents are effective against actively replicating 
virus and prevent new infection; however, they fail to 
eliminate the latent reservoirs. Hence there is an urgent 
need to develop novel therapies that can eliminate the 
latent viral reservoirs. It is established that CD4+ resting 
memory T cells are the latent cells in vivo [9, 10], that are 
non permissive for viral gene expression. However, the 
mechanism(s) and the factors involved in this process are 
not fully defined. Though resting CD4+ T cells are the 
main reservoir for the latent virus, additional reservoirs 
include other cell types of T cell linage, including naïve T 
cells; macrophages; and cells of the central nervous sys-
tems [11–15]. Various methods have been proposed to 
activate and kill the latently infected cells; however, these 
strategies have resulted in variable outcomes in clinical 
trials, indicating that a better understanding of the fac-
tors and/or mechanisms regulating reactivation of latent 
virus is needed.
Studies have shown that viral latency is facilitated in 
part by transcription factors such as NF-κB, AP-1, NFAT 
and histone modification as well as DNA methylation in 
HIV-1 LTR in different HIV latency cell models and in 
primary cells [16–21]. However, compounds/reactiva-
tors targeting histone acetylation (SAHA, suberoylanilide 
hydroxamic acid), NF-κB activation (prostratin) or T cell 
activation (α-CD3/α-CD28) do not consistently reacti-
vate the latently infected cells in patients, suggesting that 
HIV-1 latency is controlled by multiple host factors and 
regulatory proteins. Similarly the ability of latency revers-
ing agents to reactivate latent HIV-1 in various in vitro T 
cell based HIV-1 latency models are also highly variable, 
suggesting that multiple factors and mechanisms are 
involved in different cell types [22–25].
In an effort to identify the factors and their regulatory 
pathways involved in reactivation mediated by a specific 
activator, we generated and integrated genome wide 
transcriptome datasets using robust Systems Biology 
approaches. As a “proof of concept”, ACH-2 cells, a T cell 
line harboring a single copy of latent HIV-1 provirus, was 
activated with SAHA, prostratin or TNF-α and transcrip-
tome analyses was performed at multiple time points to 
identify host cellular transcripts and upstream transcrip-
tion factors (TFs) that regulated activation. ACH-2 cells 
have a mutation in TAR region affecting the Tat mediated 
transactivation, this helps to identify the factors involved 
in early stages of HIV-1 latency reversal in the absence 
of viral proteins including Tat, though absence of effec-
tive Tat-TAR axis can promote latency status of infected 
cells. Our methods were used to reconstruct dynamic 
signaling and regulatory networks for these activators. 
The reconstructed model identified several key regula-
tors for each treatment, and the specific set of genes they 
control either directly or indirectly. Furthermore, spe-
cific cellular factors and signaling pathways identified 
by SDREM analyses are validated using small molecule 
inhibitors. Our combinatorial approach was able to iden-
tify the key pathways involved in latent HIV-1 reactiva-
tion. JAK-STAT appears to have a critical role in HIV-1 
transcription independent of the method of reactiva-
tion. Additionally, regulatory pathways involving JNK is 
required for virus reactivation by SAHA in ACH-2 cells, 
whereas, ERK1/2 and NF-κB, pathways are involved with 
reactivation with prostratin and TNF-α, respectively. 
Evaluation using another HIV-1 latent cell line, J-Lat as 
well as human primary resting T cells also confirmed 
that many of the factors associated with latency revers-
ing agents are similar in different cell lines, though dif-
ferences are also noted. Here we have demonstrated that 
temporal transcriptional analysis assessed by SDREM is a 
useful tool to identify the key regulators and/or pathways 
involved in latent HIV-1 reactivation.
Methods
Cell culture and reagents
ACH-2, A3.01 and J-Lat cell lines were obtained through 
the NIH AIDS Research and Reference Reagent Program, 
Division of AIDS, NIAID, NIH (ACH-2 cell line from 
Dr. Thomas Folks [26, 27]; J-Lat Full Length Clones from 
Dr. Eric Verdin [28, 29]) and were maintained in RPMI 
containing 10 % FBS, 1 % l-glutamine and 1 % penicillin–
streptomycin (GIBCO). Multiple J-Lat cell lines derived 
from the same parent cell line, Jurkat T cell line, were 
included in our study. These cell lines contain either a full 
length GFP reporter virus (HIV-1 ΔNΔE-GFP) (3 cell 
clones—FL8.4, FL9.2 and FL10.6) or LTR–Tat-IRES-GFP 
(5 cell clones—TG82, TGA1, TGA2, TGA7 and TGH2). 
SAHA (suberoylanilide hydroxamic acid), prostratin, 
TNF-α and PHA-M (Phytohemagglutanin-M) were 
obtained from Sigma-Aldrich and R&D Systems. IΚK2 
inhibitor V and SB203580 were obtained from CalBio-
chem. FK506 (Tacrolimus), Cyclosporin A and SB600125 
were purchased from Abcam Biochemicals. Rottlerin, 
U0126 and WP 1066 were obtained from Sigma-Aldrich, 
Cell Signaling Technology and Enzo Life Sciences, 
respectively. In time kinetic experiments, the cells were 
treated with a compound and cells were collected at 
multiple time points from the single pool to reduce vari-
ability between time points within an experiment (paired 
design, repeated measures).
Purification of primary resting CD4+ T cells
Peripheral blood mononuclear cells were isolated from 
HIV-1 seronegative whole blood by Ficoll-Paque density 
gradient centrifugation (GE Healthcare). CD4+ T cells 
were purified by magnetic bead negative selection using 
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a CD4+ T cell isolation kit (Miltenyi Biotec) and resting 
CD4+ T cells (rCD4+) were purified by magnetic bead 
negative selection using anti-CD25, anti-CD69 and anti-
HLA-DR antibodies (Miltenyi Biotec).
Primary T cell treatment, infection and stimulation
Freshly isolated rCD4+ T cells were cultured at a density 
of 1–2 × 106 cells/mL in RPMI-1640 supplemented with 
10  % FBS and pencillin/streptomycin/l-glutamine (100 
Units/mL; 100  µg/mL; 0.292  mg/mL respectively, Life 
technologies) along with the chemokine CCL19 (100 nM, 
R&D systems), as described previously [30]. After being 
in culture for 2  days, rCD4+ T cells were infected with 
HIV-1LAI (MOI = 1, titered on GHOST cells) for two to 
3 h at 37 °C. The cells were then washed twice with media 
to remove any free virus and replaced back at 37  °C in 
fresh media. Two and four days post-infection, rIL-2 
(10  U/mL, Roche) and EFV (300  nM, NIH AIDS Rea-
gent Repository) were added to each well to inhibit any 
new rounds of infection that may occur. Seven days post-
infection, the cells were washed again with media and 
plated in a 96-well plate at 100,000 cells/well. Cells were 
either stimulated with anti-CD3/CD28 (3 beads/cell, Life 
technologies) or 5 µM prostratin, and one of five inhibi-
tors: 10 µM AZD 6244, 25 µM IΚK2-V, 50 µM SP600125, 
5  µM WP1066 or 50  µM SB203580 were included at 
either 4  h prior to or 4  h post stimulation. Four days 
post-stimulation, half of the media was replaced with 
fresh media containing rIL-2 (10 U/mL, Roche) and EFV 
(300 nM).
Flow cytometry
Surface staining of the cells was performed with CD2, 
CD3, CD4, CD28 antibodies or isotype controls as 
described [31]. For the detection of intracellular p24, 
fixation and permeabilization were carried out using the 
CytoFix–CytoPerm kit (BD Biosciences, Mountainview, 
CA, USA) and intracellular p24 staining was performed 
at room temperature for 1 h using 1 µl of anti-p24-FITC 
antibody (Coulter, Miami, FL, USA; clone KC47) per 
106  cells, followed by two washes in Perm-Wash buffer, 
and finally resuspended in FACS buffer. Samples were 
analyzed using Fortessa (BD Biosciences) with 20,000-
gated events acquired for each sample, and the results 
were analyzed using FlowJo software (Tree Star, Inc., OR, 
USA).
Real‑time RT‑PCR analysis
Total RNA extracted using RNeasy Mini Kit (Qiagen, 
CA, USA) was used to quantitate RPLPO, Multiply 
Spliced RNA (MS-RNA) and HIV-1 gag–pol transcripts 
by real-time PCR as described before [32, 33]. Briefly, a 
two-step RT-PCR was performed as follows: RNA was 
reverse transcribed using Taqman Reverse Transcription 
Reagents (Applied Biosystems, Foster City, CA, USA); 
Real-time PCR was carried out in triplicate using primer/
probe sets specific for MS-RNA, HIV-1 gag-pol and ribo-
somal large protein (RPLPO, Applied Biosystems). The 
comparative CT method was used to determine the rela-
tive level of MS-RNA and HIV-1 gag transcripts by nor-
malizing to the RPLPO control transcript.
For HIV-1 RNA quantification from primary cell cul-
ture, culture supernatant samples were spun at 16,100×g 
for 70  min to pellet HIV-1 virions. HIV-1 RNA was 
extracted from the virions using the RNeasy PLUS Mini 
Kit per the manufacturers protocol (Qiagen). To quan-
tify total HIV-1 RNA in the culture supernatant, the 
extracted HIV-1 RNA samples were first converted into 
cDNA followed by real-time PCR using the protocols 
previously described [34] with few modification (Affini-
tyScript Multiple Temperature RT (Agilent technolo-
gies) was used instead of Superscript II RT). The primers 
and probe used to quantify HIV-1 RNA were used as 
described previously [35]. High copy number HIV-1 
RNA transcripts were serially diluted to use as a RNA 
standard also as previously described [35].
Transcriptome profiling and data analysis
Illumina HT-12 V4 array bead chips (Illumina, Inc., San 
Diego, CA, USA) were used for whole genome transcrip-
tome analysis for mRNA profiling after different treat-
ment of ACH-2 cells. Each array targets about 47,231 
probes that include 28,688 well-characterized or anno-
tated coding transcripts along with 11,121 coding tran-
scripts with provisional annotation and remaining being 
non-coding transcripts and splice variants. RNA samples 
(1  μg) were labeled using the ‘TotalPrep RNA’ labeling 
kit (Ambion), reverse transcribed to cDNA; cRNA was 
synthesized from cDNA with labeling and hybridized 
onto array bead chips overnight on rocker and scanned 
on ‘iScan system’, according to the manufacturer’s proto-
cols as well as standardized protocols developed by the 
Genomics and Proteomics Core Laboratories at the Uni-
versity of Pittsburgh. Datasets will be deposited in NCBI 
gene expression and hybridization array data repository 
GEO database. The data were analyzed using GenomeS-
tudio to identify the differentially regulated gene tran-
scripts. The data were normalized by rank invariant 
method and no background subtraction was included, 
additionally, the missing samples were excluded. For 
calculating differential expression, the Illumina custom 
model was included along with multiple testing correc-
tions using Benjamini and Hochberg False Discovery 
Rate, which is a standard methodology recommended 
by GenomeStudio to compare paired data [36]. The dif-
ferential score is a transformation of the p value that 
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provides directionality to the p-value based on the differ-
ence between the average signal at time point zero versus 
different time points. The formula used for calculating 
Differential score = 10 × (Mean signal intensity at given 
time point (μt) − Mean Signal intensity at time point 0 
(μt0)) × Log10p. A Differential score of ±13, correspond-
ing to p < 0.05 was considered as the cut-off to identify 
significantly regulated transcripts.
Gene set enrichment analysis (GSEA)
To identify the biological process/function associated 
at virus replication at initial virus reactivation and later 
productive stage, the transcriptome data was analyzed 
using GSEA/MSigDB (version 4.0) (http://www.broadin-
stitute.org/gsea/msigdb/annotate.jsp) [37, 38]. First, a list 
of genes (regulated by more than twofolds, with p-value 
<0.05) was obtained for the time point in each treatment 
corresponding to virus reactivation and gag production/
virus release (Multiple probes for the same gene was inte-
grated together and analyzed at gene level). The identi-
fied genes were then analyzed using GSEA, with an FDR 
q-value below 0.05. This represents genes coordinately 
regulated in predefined gene sets from various biological 
pathways.
Signaling and dynamic regulatory events miner (SDREM)
To reconstruct signaling and regulatory networks acti-
vated following different treatments, we used SDREM as 
described [39, 40]. For the regulatory part, SDREM inte-
grates condition specific time series gene expression data 
with global protein-DNA interaction data to identify bifur-
cation events in a time series (places where the expression 
of previously co-expressed set of genes diverges)–and the 
transcription factors (TFs) controlling these split events. 
While some TFs are transcriptionally activated, others 
are only activated post translationally via signaling net-
works. To identify and explain these TFs, the second part 
of SDREM links sources (host proteins that directly inter-
act with the virus, in this case human proteins that were 
determined to physically interact with HIV-1 viral proteins 
[41]) to the TFs determined to regulate the regulatory net-
work. This part of SDREM uses experimentally derived 
protein–protein interaction (PPI) from Biogrid and pro-
tein modification data [42] to infer such pathways—while 
imposing the constraint that the direction of PPI in the 
inferred pathways is consistent. These two parts (regula-
tory and signaling reconstruction) iterate a fixed number 
of times until the final network is obtained. See Gitter and 
Bar-Joseph [39] for complete details.
Immunoblotting
ACH-2 cells or A3.01 cells were treated with SAHA, 
prostratin, or TNF-α, and at the indicated time point, 
the cells were washed twice with PBS and lysed in RIPA 
buffer containing 50  mM Tris (pH 7.5), 150  mM NaCl, 
1 % Triton X-100, 1 mM sodium orthovanadate, 10 mM 
sodium fluoride, 1.0  mM phenylmethylsulfonyl fluoride, 
0.05 % deoxycholate, 10 % sodium dodecyl sulfate, apro-
tinin (0.07 trypsin inhibitor unit/ml), and the protease 
inhibitors leupeptin, chymostatin, and pepstatin (1  μg/
ml; Sigma). Cell lysates were clarified by centrifugation, 
and total cell lysates (30  μg) were separated on a 12  % 
sodium dodecyl sulfate–polyacrylamide gel (SDS-PAGE) 
electrophoresis gel, transferred, and immunoblotted with 
anti-NT5C3 (santa cruz biotechnology) or anti- tubulin 
antibodies. The blots were developed using an ECL kit 
(Amersham Biosciences, Piscataway, NJ, USA).
Gag p24 ELISA
Following different treatment of ACH-2 and J-Lat cells, 
supernatants were collected and analyzed for the amount 
of HIV-1 p24 Gag. Gag (p24), was measured by using 
enzyme-linked immunosorbent assay (ELISA) kit (Zep-
tometrix, Buffalo, NY, USA) according to the manufac-
turer’s protocol.
Statistical analysis
The results from p24 ELISA, comparative reactiva-
tion studies, and inhibitor experiments are expressed as 
mean ± standard deviation. The data are analyzed using 
the Student’s t test for paired samples.
Results
Multiple complementary factors are involved in reversal 
of latent HIV‑1
Comparative studies using multiple activators to reacti-
vate HIV-1 from latency have resulted in different levels 
of virus reactivation [43–46], suggesting a role for mul-
tiple factors in virus reactivation. Here we used a well-
characterized ACH-2 T cell line based HIV-1 latency 
model as our model cell line to validate the Systems Biol-
ogy approach to identify the cellular factors and pathways 
involved in reversal of latent HIV-1 by SAHA, prostra-
tin and TNF-α. ACH-2 cells were treated with different 
concentrations of SAHA, prostratin, or TNF-α for 18 h. 
Alternatively, the cells were also activated using αCD3/
αCD28 antibody for 3  days, and virus reactivation was 
measured by intracellular p24 staining (Fig. 1a). Phorbol 
12-myristate 13-acetate (PMA) was used as a positive 
control. In the presence of vehicle (DMSO) control alone, 
13–20 % of cells are positive for p24 Gag as measured by 
flow cytometry. PMA (positive control), which is a potent 
activator of protein kinase C (PKC) reactivated 90–95 % 
of the cells in 18 h, suggesting that the ACH-2 cells have 
a wide dynamic range (Fig. 1a) and can serve as a sensi-
tive model for estimating the potency of HIV-1 latency 
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reactivators and to elucidate the contribution of cellular 
factors and signaling pathways in HIV-1 transcription 
regulation. Addition of clinically relevant concentration 
of SAHA (0.5 μM) reactivated 57–65  % of ACH-2 cells 
as detected by positive p24 Gag staining, and increas-
ing concentrations (5 µM) of SAHA resulted in ~95 % of 
them positive for p24 Gag (Fig. 1b). Similarly we observed 
a dose dependent increase in the reactivation of latent 
HIV-1 in ACH-2 cells, with increasing concentrations 
of prostratin and TNF-α as well. At 0.2 μM concentra-
tion, prostratin activated 32–37 %, whereas, at 2 μM, the 
percentage positive cells increased to 87–94 %. TNF-α, a 
potent activator of latently infected cells exhibited similar 
activation levels at 10 ng/ml concentration. Interestingly, 
stimulation with and anti-CD3 and anti-CD28 antibod-
ies failed to activate significant amount of the latent virus 
in ACH-2 cells (Fig. 1b). Flow cytometry analyses of sur-
face expression of CD3, CD28 and CD2 suggested that 
only less than 15  % of ACH-2 cells expressed CD3 and 
CD28 molecules, and less than 10 % of the cells express 
CD2 (Additional file 1: Fig. S1) that are required for TCR 
mediated activation, respectively. These results correlate 
with the absence/minimal response observed in ACH-2 
cells when treated with αCD3/αCD28 antibodies.
To assess whether these activators could have an addi-
tive effect in reversal of latent virus, ACH-2 cells were 
treated with a combination of submaximal concentra-
tions of these compounds to reactivate latent virus 
(Fig.  1c). Results indicate that combining SAHA and 
prostratin resulted in an increase in percentage of cells 
expressing p24 Gag. Treatment with SAHA or prostratin 
alone, showed 57–65 and 32–37 % of p24 positive cells, 
respectively, whereas a combination of these two acti-
vators resulted in 87–92  % of p24 positive cells. These 
results suggest an additive effect, implying that independ-
ent cellular factors are involved in SAHA and prostratin 
mediated latent HIV-1 reactivation and that these factors 
could complement each other to potentiate the effect. A 
similar increase in percentage of p24 Gag positive cells 
was observed when SAHA was combined with TNF-α, 
an increase from 23–28 to 83–87  % p24 positive cells. 
Similarly, when prostratin and TNF-α were combined 
together, the p24 positive cells increased to 46-62  %, a 
lesser extent than the additive effect, suggesting that 
prostratin and TNF-α may share few common cellular 
factors and pathways in virus reactivation. Combining 
SAHA, prostratin and TNF-α together resulted in maxi-
mum reactivation (93–97 % p24 positive cells), similar to 
that observed in PMA treated positive control. Collec-
tively, these results suggest that HIV-1 reactivation from 
latency is mediated by multiple pathways involving dif-
ferent cellular factors that are complementary as well as 
common depending on the context of the activator used.
Kinetics of latent HIV‑1 reactivation in ACH‑2 cells indicates 
that transcriptional reactivation of viral RNA is an early 
event
The kinetics of latent viral reactivation were assessed to 
understand the timing and sequence of events leading 
to the transcriptional switch from latency to productive 
infection and virus release. ACH-2 cells were treated 
with SAHA, prostratin or TNF-α and synthesis of viral 
transcripts and virus production/release was measured 
at 2, 4, 6, 8, 10, 12 and 18 h post activation (Fig. 2b–d). 
Gag (p24) positive cells were assessed by p24 intracellular 
staining and flow cytometry (Fig. 2a). Intracellular stain-
ing for p24 Gag indicates that ACH-2 cells treated with 
SAHA resulted in a shift from background level of ~20 
to ~80 % 10 h post treatment and reached the maximum 
of 95 % with associated increase in MFI, suggesting that 
SAHA induced viral Gag production required 10  h. In 
case of prostratin, a less dramatic shift in cells express-
ing p24 Gag was seen in 6–8 h, whereas, TNF-α exhib-
ited a slow increase at 6 h post stimulation and reached 
the maximum at 12  h. Together, these results support 
that SAHA, prostratin and TNF-α might utilize diverse 
mechanisms, with varying kinetics leading to reactivation 
of HIV-1 in ACH-2 cells.
To understand the time kinetics required for HIV-1 
transcriptional reactivation in these cells, multiply 
spliced viral transcripts and unspliced gag RNA was 
assessed over time (Fig.  2b). Total RNA was extracted 
from part of the cells collected at the same time points 
to assess MS-RNA and unspliced Gag RNA (Fig.  2b, 
c) and virus released in the supernatant was measured 
by p24 ELISA (Fig.  2d), as described in materials and 
(See figure on previous page.)
Fig. 1 Dose dependent reversal of latent HIV‑1 in ACH‑2 cells by SAHA, prostratin and TNF‑α. a ACH‑2 cells were treated with different reactivat‑
ing agents for 18 h and p24‑Gag was estimated by intracellular staining. A representative figure denoting intracellular HIV‑1 p24 Gag detected by 
flow cytometry (N = 4) is shown here. Viable cells were gated based on side and forward scatter dot plot and the p24 positive cells were detected 
by anti‑p24‑FITC antibody b The percentage of HIV‑1 Gag‑p24 positive cells from multiple experiments (N = 4) are shown, to demonstrate the 
dose dependent response of ACH‑2 to different activating reagents. Error bars represent standard deviation. c Effect of combination of reactivat‑
ing agents. For comparison of results across samples from multiple experiments, HIV reactivation observed upon PMA (100 nM) treatment minus 
background (DMSO) was considered as 100 %. Error bars represent standard deviation (N = 4). *p < 0.05 by student t test
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methods. Results indicate that prostratin initiated virus 
transcription within 2–4  h and that the peak expres-
sion of MS-RNA was reached at 6  h. Six hours post 
treatment there was a gradual decrease in the multiply 
spliced RNA and a corresponding increase in full-
length gag transcripts occurred (Fig.  2b, c). The lesser 
fold change in cellular gag transcripts can be attributed 
to the packaging of full length gag transcripts in virus 
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Fig. 2 Time kinetics of p24 gag protein expression, synthesis of viral transcripts and virus release. a HIV‑1 Gag positive cells were detected by 
intracellular staining for p24‑Gag protein at indicated time points following treatment of ACH‑2 cells with SAHA, prostratin or TNF‑α. b Multiply 
spliced HIV‑1 RNA transcripts, and c Unspliced HIV‑1 (Gag‑pol) RNA transcripts were detected by Real time PCR at indicated time points. The aver‑
age fold changes in RNA transcripts over time zero observed in two independent experiments done in triplicates is shown. RPLPO (large ribosomal 
protein) was included for normalization. d The amount of virus released in the supernatant was detected by p24 ELISA and the p24 value at time 
zero was subtracted from individual time points to calculate the new virus released over time. The average of two independent experiments done 
in triplicate is shown
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particles and their release in the supernatant, as meas-
ured by an increase in p24 virus Gag (Fig.  2d), result-
ing in sinusoidal curves of gag transcripts. In case of 
SAHA, we observed an increase in multiply spliced 
viral transcripts around 4–6  h, which was to a lesser 
extent than the fold change observed in prostratin. In 
case of gag transcripts, the increase was also to a lesser 
extent in comparison to prostratin occurring around 
10  h. This correlates with the detection of p24 Gag by 
flow cytometry. The release of virus particles in SAHA 
as measured by an increase in p24 Gag protein in the 
supernatant was observed around 10 h. TNF-α resulted 
in an increase in multiply spliced transcripts by 6  h 
though the increase was very modest in multiple experi-
ments; similarly, the increase in gag transcripts was 
observed around 10 h. Virus released in supernatant in 
TNF-α treatment of ACH-2 cells was similar to SAHA, 
where an increase in p24 was detected by 10 h and con-
tinued to increase over time. These results suggest that 
HIV-1 reactivation at transcription level in ACH-2 cells 
is an early event occurring within the initial 4–6 h post 
reactivation. Additionally, we noted that reactivation of 
latent virus in ACH-2 cells is a sequential process simi-
lar to acute HIV-1 infection in T cells, where the initial 
transcription initiation is followed by transcription of 
multiply spliced viral RNA transcripts, and a subse-
quent shift to full length gag transcripts and the final 
stage of viral RNA packaging and virus release.
Transcriptome analysis to identify specific factors involved 
in virus reactivation
In an effort to identify the cellular factors and signal-
ing pathways that are modulated following treatment 
of ACH-2 cells with different reactivating agents, tran-
scriptome analyses were performed at multiple time 
points following treatment of cells with reactivating 
agents. Results indicate that multiple cellular tran-
scripts were altered over time (Fig.  3a; Table  1). Inter-
estingly, significant changes in cellular transcripts were 
observed within 2  h post treatment, with the largest 
changes induced by SAHA—264 host cellular gene tran-
scripts were identified as significantly upregulated and 
88 transcripts significantly downregulated. Prostratin, 
significantly increased the transcripts for 14 genes while 
none of the transcripts were significantly decreased by 
2  h. For TNF-α, 83 gene transcripts were significantly 
upregulated and 46 cellular transcripts were signifi-
cantly downregulated at this time point. Evaluation of 
cellular transcriptome data over time indicates that, 
the changes in cellular transcripts are the greatest with 
SAHA and relatively lesser with prostratin and least 
with TNF-α. Though the number of transcripts that 
were altered in either direction (up/down regulated) 
were comparable across all treatments, for SAHA the 
differential score for transcripts (a measure of statisti-
cal significance of the change and fold change in tran-
script levels) was symmetrically distributed in both the 
positive and negative direction, whereas, with prostra-
tin and TNF-α, there were more cellular transcripts 
that were significantly upregulated than those that were 
down regulated. 
A single copy of HIV-1 in ACH-2 is integrated in the 
intron between exons 5 and 6 in NT5C3A, variant 1 on 
chromosome 7 [47]. Analysis of transcriptional changes 
in cellular genes around this region clearly identifies 
that NT5C3 as the only host gene that is consistently 
induced with the reactivation of the virus in ACH-2 
cells to 7.4- 18.5 fold. None of the closely associated 
gene transcripts namely RP9, BBS9, FKBP9 or RP9P 
changes more than 1.4 to 0.9 fold with reversal of HIV-1 
latency (Additional file  2: Table S1, Additional file  3: 
Fig. S2A). Time kinetics of changes in NT5C3 tran-
scripts identifies that transcripts are induced as early 
as 2  h following treatment of ACH-2 cells with pros-
tratin and TNF-α, and the levels continue to increase 
over time. With SAHA an increase in NT5C3 transcript 
is noticed at 4  h and this increase remains progressive 
and sustained, finally resulting in highest fold change of 
18.5 in comparison to prostratin (12.6 fold change) and 
TNF-α (7.4 fold change) (Additional file  3: Fig. S2B). 
Induction of NT5C3 transcripts as detected by RNA 
hybridization in Illumina HT-12 chip was also detected 
at the protein level by western blot using NT5C3 spe-
cific antibody (Additional file 3: Fig. S2C). It is observed 
that the NT5C3 protein is not present in the media con-
trol, whereas detected upon treatment with prostratin, 
SAHA or TNF-α. Comparison of changes in protein 
level over time with the parent cell line, A3.01 cells, 
indicates that NT5C3 is expressed in A3.01 cells even 
in the absence of latency reactivating agents, Additional 
file 3: Fig. S2C, lane 5, suggests that, the integration of 
HIV-1 virus and its latent state in ACH-2 cells is asso-
ciated with suppression of host cellular gene, NT5C3. 
With the reactivation of latent HIV-1 with either pros-
tratin, SAHA or TNF-α is associated with reversal of 
this inhibition of NT5C3 expression.
Gene expression data sets were assessed to identify 
the pathways or major functions that are targeted by the 
reactivators using GSEA as described [37]. Results pre-
sented in Fig. 3b focused on time points corresponding 
to the expression of viral transcripts and Gag synthesis/
release indicate that the differentially expressed genes 
prior and/or during the time point represent primarily 
genes belong to transcription factors, protein kinases, 
cell differentiation markers and cancer related genes as 
well as cytokines and growth factors.
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Transcriptional regulators and pathways involved in the 
reactivation of HIV‑1
Next, to identify the upstream regulators including the 
transcription factors and their associated signaling mol-
ecules, the time series transcriptome data correspond-
ing to each of these treatments were used to reconstruct 
dynamic signaling and regulatory networks using 
SDREM (Fig.  4a–f). Based on our observations from 
viral transcriptome analysis, the reactivation of latent 
HIV-1 in ACH-2 cells was initiated as early as 4–6  h 
following treatment with SAHA, prostratin or TNF-α. 
Hence for SDREM analysis, the transcriptome data were 
Fig. 3 Analysis of whole genome transcriptome data. a Time kinetics of whole genome transcriptome analysis in ACH‑2 cells treated with SAHA, 
prostratin and TNF‑ α. Genome Studio was used to analyze transcriptome data obtained from Illumina HT‑12 V4 array bead chips for ACH‑2 cells 
treated with different reactivating agents at indicated time points. A differential score of ±13 (dotted line) corresponding to a p < 0.05 was used to 
identify the significant genes. Each data point corresponds to a differential score of an individual transcript calculated from results obtained in two 
independent experiments. b Dysregulated genes (p‑value <0.05 and fold change ±2) from GenomeStudio transcriptome analysis were analyzed 
using MSigDB version 4.0 (http://www.broadinstitute.org/gsea/msigdb/annotate.jsp). The stacked bar graph represents the number of genes in 
each functional category for different time points in ACH‑2 cells treated with SAHA, prostratin or TNF‑α
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divided into two sets—(1) initial reactivation phase, cor-
responding to time points before the expression of viral 
transcripts; and (2) virus production phase, associated 
with time points post viral transcripts synthesis. The 
transcriptome changes in the initial reactivation phase 
are key for switching on the latent HIV-1 transcription 
and are the consequence of reactivating agents, while 
changes in the virus production phase are due to the 
combined effects of reactivating agents and viral prod-
ucts. Results from the SDREM analyses corresponding to 
initial reactivation phase (6 h post treatment) with SAHA 
suggest that TFs–JUN, NFATC1-4, HOXA4, TCF7L2, 
SRY, CEBPE, and FOXO4 are responsible for changes 
observed in the cellular transcripts in the initial 2 h. Simi-
larly FOXO4, MTF1, NR3C1, NFE2L1, FOXO1, FOXL1, 
TBP, ATF2 and SRY were predicted to be responsible for 
changes observed in the cellular transcripts observed 
between two and 4 h. No additional changes in TFs were 
observed at 4–6 h. Identification of regulatory networks 
using the transcriptome data from ACH-2 cells acti-
vated with SAHA is presented in Fig.  4a. As SAHA is 
well characterized as an inhibitor of histone deacetylase 
enzyme (HDAC), we included all isoforms of HDACs as 
the source molecules for the SDREM analysis. The down-
stream nodes representing the signaling and regulatory 
components constructed by SDREM are represented in 
Fig. 4b; Table 2. This includes the top 30 factors that are 
predicted to be involved in signal transduction mediated 
downstream events of HDACs following treatment of 
ACH-2 cells with SAHA.
Similar analyses were performed for prostratin induced 
reactivation in ACH-2 cells (Fig.  4c, d). Results indicate 
that TFs—HNF1A, POU2F1, SPI1, ETS1, LEF1, POU2F1, 
CEBP, SMAD, TCF7L2, RELA, GATA, STATs, BRCA1, 
ZEB1, FOXC1 and MZF1 are regulating the transcrip-
tional changes observed at 4 h post prostratin treatment 
(Fig. 4c). It is also noted that the expression levels of ETS1 
and LEF1 are increased and the expression of GATA3, 
STAT5A and CEBPB is reduced at this time point. As 
prostratin is an activator of Protein Kinase C (PKC), PKC 
was included as a source and the regulatory pathways 
and factors that were predicted to mediate the changes 
observed in the regulatory models are identified in 
Fig. 4d. The top 30 factors predicted by SDREM as criti-
cal for prostratin effects in ACH-2 cells are also presented 
in Table 2. Results indicate that MAPK1, SMAD2/4, SRC, 
MAX, GSK3B, and LEF1 are identified as unique fac-
tors involved in prostratin induced signaling and predict 
PRKCQ as the main driving factor responsible for the 
changes observed in cellular transcripts during early time 
duration of 0–4 h following prostratin treatment.
Unlike prostratin, TNF-α exhibited delayed reactiva-
tion kinetics in ACH-2 cells. SDREM analysis of time 
kinetic data obtained from TNF-α treated cells pre-
sented in Fig.  4e, suggests that TFs- VDR, RUNX1, 
SP1 and SP3 are contributing to the differential regula-
tion of cellular transcripts observed at 2  h. TFs related 
to NF-κB—NF-κB1, NF-κB2, RELA; JAK-STAT related 
factors—STAT4, STAT5A, STAT6; CEBPA, CEBPE, 
GATA3, CUX1, ETV4, ETS1, FKBP4, CD40, ZEB1 are 
identified to be responsible for changes observed in the 
cellular transcripts at 2 and 4 h. The regulatory pathways 
and factors likely responsible for changes in TFs origi-
nating from TNFRSF1A and TNFRSF1B are indicated 
in Fig.  4f and Table  2. TFs, Jun, Myc, RelA, STAT1/3, 
TP53, NR3C1, CEBPB, and CREBBP, which are known to 
bind to HIV-1 LTR were present in all three treatments. 
Together these results suggest that specific transcription 
factors and their associated cellular signaling pathways 
are involved in HIV-1 reactivation in the ACH-2 cell line. 
It should be noted that SDREM identifies the upstream 
regulatory factors as the most probable factors responsi-
ble for changes observed in the transcripts at the identi-
fied time point and hence changes (activation/inhibition) 
in these upstream factors occur prior to the time points 
when the changes in transcripts were evaluated.
Table 1 Differentially regulated cellular transcripts in  ACH-2 at  indicated time points following  treatment with  SAHA, 
prostratin or TNF-α
Comparison of differentially regulated cellular transcripts at multiple time points in comparison to time 0 (before addition of latency reversing agents) in ACH-2 
cells. A differential score of ±13 corresponding to a p < 0.05 was used to identify the significant genes. The number of cellular gene transcripts that are significantly 
upregulated are in roman and that which are significantly downregulated are italicized
2 h 4 h 6 h 8 h 10 h 12 h 18 h
SAHA 264 627 1347 2401 1650 2729 2511
88 400 738 1092 1450 1589 1852
Prostratin 14 105 119 238 348 379 648
0 22 33 107 361 436 626
TNF‑α 83 68 54 66 316 119 243
46 34 50 41 458 116 308
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Fig. 4 Reversal of latent HIV‑1 model—SDREM analysis. Whole genome transcriptome data in ACH‑2 cells at multiple time points were analyzed 
by SDREM for a, b SAHA; c, d Prostratin; e, f TNF‑α. a, c, d represent the regulatory part of the model, where each path represents a collection of 
gene expression profiles; x‑axis denotes the time points for each treatment when the gene expression was measured and the y‑axis shows log2 fold 
change in expression. TFs that are predicted to control the split are included at indicated time points (TFs are included only the first time they are 
active along a regulatory path). TFs in red or blue indicate that transcripts of these TFs were also observed to be significantly increased or decreased 
respectively. The size of the node indicates the relative number of genes regulated. b, d, f represent oriented interaction network starting from 
upstream proteins (source; red), predicted signaling proteins (blue) and active TFs (green). The boldness of the edge between two nodes, indicate the 
number of pathways between the two
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Validating the predicted cellular factors and TFs in latent 
HIV‑1 reactivation in ACH‑2 cells by specific inhibitors
SDREM analysis has identified both common and unique 
TFs as the key regulators of cellular transcripts in ACH-2 
cells, when treated with SAHA, prostratin and TNF-
α. Based on these predictions we performed follow up 
experiments to validate the role of predicted factors in 
reactivation of latent HIV-1 in ACH-2 cells. First, we 
evaluated the ability of IΚK2 inhibitor V (NF-κB inhibi-
tor); Tacrolimus (FK506), Cyclosporin A (CsA)—NFAT 
inhibitors; SP600125 (JNK inhibitor); SB203580 (p38 
inhibitor); U0126 and AZD6244—ERK1/2 inhibitor; 
WP1066 (JAK-STAT inhibitor); and Rottlerin (PKC 
inhibitor) to inhibit SAHA, prostratin and TNF-α medi-
ated reactivation of HIV-1. ACH-2 cells were pretreated 
with inhibitors for 4  h and activated with SAHA, pros-
tratin or TNF-α and the p24 positive cells were assessed 
by flow cytometry (Fig. 5a). It is observed that both Rot-
tlerin and SP600125 completely abrogate SAHA induced 
virus reactivation suggesting that the PKC→JNK→JUN/
ATF pathway with related downstream TFs, has a major 
role in SAHA induced HIV-1 reactivation in these cells, 
as predicted by our model (Fig. 4a, b; Table 1). Interest-
ingly, p38 inhibitor, SB203580 further increased the per-
centage of reactivated HIV-1 virus (Fig.  5a), suggesting 
that SB203580 reactivates latent HIV-1 using cellular 
pathways much different from those used by SAHA.
In the case of prostratin, IKK2 inhibitor V, SP600125, 
U0126, AZD6244 and Rottlerin have a significant effect in 
preventing virus reactivation, suggesting that prostratin 
uses multiple alternate pathways involving NF-κB, JNK, 
ERK1/2 and PKC to induce HIV-1 reactivation (Fig.  4c, 
d). These results correlate with the SDREM prediction 
for prostratin suggesting a major role for ERK1/2. Simi-
larly, SDREM analysis was accurate in identifying factors 
involved in TNF-α induced HIV-1 reactivation, which 
involves NF-κB, JNK and PKC, but not NFAT. p38 inhibi-
tor did not increase prostratin or TNF-α mediated HIV-1 
reactivation. The percentage of cells expressing p24 was 
significantly below the background expression observed 
with DMSO, suggesting that the JAK → STAT pathway is 
involved in regulating HIV-1 LTR activity. Irrespective of 
reactivation agents, STATs were also identified as a com-
mon factor in SDREM analysis for all these activating 
agents. Furthermore, it is important to note that no cellu-
lar toxicity was observed in these cells with these inhibi-
tors, with the exception of WP1066 and Rottlerin, which 
showed 40–60  % reduction in cell viability (Fig.  5b); 
therefore only live cells were gated in flow cytometry 
based assessment of p24 positive cells. Additionally, 
dose dependent inhibitory effects can be observed with 
WP1066 and Rottlerin, and consistent inhibition was 
noted at lower concentration, when the associated cellu-
lar toxicity was minimal (Additional file 4: Fig. S3).
ACH-2 cells were incubated with the inhibitors in 
the absence of reactivating agents, to evaluate whether 
these inhibitors could potentially modulate HIV-1 tran-
scription. Results indicate that only the p38 inhibi-
tor–SB203580 and JAK-STAT inhibitor–WP1066 
significantly altered the HIV-1 transcription (Fig.  5c). 
WP1066 reduces the basal level HIV-1 transcription in 
ACH-2 cells suggesting a role for STAT in HIV-1 tran-
scription. SB203580 increased HIV-1 transcription from 
15 to 42  % at 16  h post treatment, suggesting that p38 
Table 2 List of  top 30 cellular factors involved in  SAHA, 
prostratin or TNF-α induced latent HIV-1 reactivation 
in ACH-2 cells
Proteins are ranked based on the “path flow” going through a protein. The path 
flow f  through a protein n is defined as follows—f (n) =
∑
p∈P I(p) · hp where 
P is the set of signaling pathways predicted by SDREM that contain the protein 
n and hp is the confidence in the existence of path p which is a product of the 
confidence in each individual edge of the path (The confidence is a number 
between 0 and 1). The proteins are ranked in descending order of the path flow 
going through them
SAHA Prostratin TNF‑α
UBC UBC UBC
CREBBP TP53 TP53
JUN AKT1 TRAF2
TP53 CREBBP BRCA1
RB1 BRCA1 JUN
RELA JUN HSP90AA1
BRCA1 NR3C1 RELA
NR3C1 SMAD3 CEBPB
CTNNB1 RELA HDAC1
SMAD3 MYC SMAD3
CEBPB HDAC1 IKBKB
MYC IKBKB STAT3
TBP CTNNB1 CREBBP
ATF2 STAT3 NR3C1
STAT3 CHUK CHUK
ATF3 HSP90AA1 ETS1
HIF1A CEBPB NFKB1
TP63 SRC MYC
FOXO1 SMAD2 STAT1
RXRA ETS1 RUNX2
STAT2 SMAD4 SUMO1
FOXO4 NFKB1 STAT5A
NFATC1 STAT1 STAT6
RUNX2 GSK3B GTF2I
E2F1 MAPK1 SP3
STAT1 STAT5A ATM
AKT1 MAX TRAF6
NFKB2 ATM RUNX1
TCF7L2 RB1 UBE2I
DAXX LEF1 GATA3
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inhibitor SB203580 could directly reactivate latent HIV-1 
in ACH-2 cells.
Validation of signaling pathways and regulatory networks 
in J‑Lat latent cells
To understand whether the TFs identified in ACH-2 cells 
are specific to these cells or commonly shared in other 
HIV-1 latent cells, we validated these TFs in other HIV-1 
latent cell lines, J-Lat cells that were developed by Jor-
dan et al. [29]. First, the dose of reactivating agents that 
resulted in maximum response in ACH-2 cells was tested 
in J-Lat cells, along with PHA-M. PMA was included 
as a positive control. Results indicate that the cell lines 
FL10.6, TGA1 and TGA2 had a wide dynamic range with 
minor variations in their response to different reactiva-
tors (Fig. 6a). Cell line FL10.6 is highly reactive to pros-
tratin, TNF-α and PMA reaching 60–80  % reactivation 
in comparison to SAHA and PHA-M (35–45 %); whereas 
TGA1 cells showed significant response (85–90  %) 
to prostratin and PMA but not to SAHA, TNF-α and 
PHA-M (35–60 %). The cell line TGA2 showed minimum 
activation with PHA-M (14–18  %) but the response to 
SAHA, prostratin, TNF-α and PMA were comparable to 
each other (~43–72 %). As previously reported these cell 
lines had different reactivity to different reactivators [28].
Next, we validated the specific TFs and regulatory net-
works in J-Lat based latency cell lines using inhibitors 
as described in our methods. Results indicate that path-
ways are similar in J-Lat and ACH-2 cells, with minor 
differences (Fig.  6b). JAK-STAT inhibitor, WP1066 and 
PKC inhibitor—Rottlerin have major effects in inhibit-
ing reactivation of latent HIV-1 in J-Lat clones (close to 
background GFP level), suggesting that these signaling 
pathways are critical for HIV-1 LTR activity (Additional 
file  5: Fig. S4). ERK1/2 inhibitor U0126 and AZD6244 
have a significant effect in inhibiting HIV-1 reactivation 
specifically in prostratin (~74–82  %), suggesting that 
ERK1/2 may be the major pathway involved downstream 
of PKC in prostratin mediated latent HIV-1 reactiva-
tion in J-Lat clones. Similarly NF-κB is the critical factor 
for TNF-α mediated reactivation in J-Lat cells (57–47 % 
inhibition with IΚK2 inhibitor V in J-Lat FL10.6 cells, 
67–83 % inhibition in J-Lat TGA1 cells and 90–94 % inhi-
bition in J-Lat TGA2 cell line). However, JNK exhibits a 
central role in activating HIV-1 LTR with SAHA, prostra-
tin or TNF-α in J-Lat cells. Interestingly, it is also noted 
that IΚK2 inhibitor V inhibited SAHA mediated reac-
tivation in J-Lat cells suggesting a role for NF-κB (~62–
83  %). This correlates with the relatively reduced ability 
of SP600125 to inhibit the SAHA mediated reactivation 
in comparison to reactivation observed ACH-2 cells (60–
70  % inhibition in J-Lat cells versus 85–95  % inhibition 
in ACH-2 cells). This suggests that when JNK mediated 
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Fig. 5 Specific cellular signaling pathways with associated host cel‑
lular factors are involved in reactivation of latent HIV‑1 in ACH‑2 cells. 
a ACH‑2 cells were pretreated with specific inhibitors IΚK2 inhibitor 
V (50 µM), FK506 (10 µM), Cyclosporin A (10 µM), SP600125 (50 µM), 
SB203580 (50 µM), U0126 (50 µM), AZD6244 (10 µM), WP1066 (5 µM), 
Rottlerin (50 µM), or vehicle control (DMSO), and 4 h later activated 
with SAHA (1 µM, white bars), prostratin (1 µM, grey bars) or TNF‑α 
(0.1 ng/ml, bars with diagonal line upwards). HIV reactivation was esti‑
mated at 12 h following reactivation, by intracellular p24 Gag staining 
by flow cytometry. For comparison of results across samples from 
multiple experiments, HIV‑1 reactivation observed in vehicle control 
pretreatment was considered as 100 % and the background (no reac‑
tivating agent) as 0 %. Error bars represent standard deviation (N = 3), 
*p < 0.05. b At the end of 16 h following addition of inhibitors, the 
live cells were evaluated by Trypan blue staining. The percentage of 
viable cells was calculated by subtracting the dead cells from total 
cells divided by total cell count. c The amount of p24‑Gag positive 
cells was estimated by intracellular p24‑Gag staining and flow cytom‑
etry. Error bars represent standard deviation (N = 3), *p < 0.05
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signaling is blocked in J-Lat, NF-κB related pathways 
could still lead to reactivation of latent HIV-1.
Time dependent inhibition of signaling pathways 
and regulatory networks in J‑Lat cells identify unique role 
for JAK‑ STAT early in latent virus reactivation
The above results identified the requirement of specific 
cellular signaling pathways and regulatory network in 
J-Lat cells upon activation by various reactivating agents. 
To identify the relationship between these specific regu-
latory networks and their role in latent HIV reactivation, 
we blocked the specific regulatory network following 
reactivation of latent virus in a time dependent manner. 
J-Lat clone FL 10.6 and TGA1 were used for these experi-
ments where the cells were stimulated with SAHA, pros-
tratin, TNF-α or PHA-M followed by blocking of specific 
signaling network by using small molecule inhibitors at 
multiple time points of 2  h intervals. Cells treated with 
inhibitor 4  h prior to stimulation was included as con-
trols, and cells stimulated with latency reactivating 
agents with no inhibitor were included as positive con-
trol and was normalized to 100  %. Results indicate that 
including the inhibitors at 4 h prior to stimulation iden-
tified specific pathways involved in latent virus reac-
tivation as in earlier experiments (Fig.  6b, c), where we 
noticed >95 % inhibition with STAT inhibitor, WP1066 in 
both the tested J–Lat cell lines, with all the tested latency 
reactivating agents (Fig.  7a–h, unfilled open bars). 
Whereas, when WP1066 was added 2 h post stimulation, 
it can be noticed that the inhibition of virus reactivation 
was reduced to 40–50  % in both SAHA and prostra-
tin. Including WP1066 after 4  h or later post treatment 
with SAHA or prostratin resulted in no effect on HIV-1 
a
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Fig. 6 Host signaling pathways and regulatory cellular factors 
involved in reactivation of HIV‑1 transcription in J‑Lat cells. a Eight 
different clones of J‑Lat cells were treated with different reactivating 
agents or DMSO for 18 h and the percentage of GFP positive cells was 
estimated by flow cytometry. Error bars represent standard deviation 
(N = 3). Cell lines b J‑Lat FL10.6, c J‑Lat TGA1, and d J‑Lat TGA2 cells 
were pretreated with specific inhibitors IΚK2 inhibitor V (50 µM), 
FK506 (10 µM), Cyclosporin A (10 µM), SP600125 (50 µM), SB203580 
(50 µM), U0126 (50 µM), AZD6244 (10 µM), WP1066 (5 µM), Rottlerin 
(50 µM), or vehicle control (DMSO), and 4 h later activated with SAHA 
(1 µM, white bars), prostratin (1 µM, grey bars) or TNF‑α (0.1 ng/ml, bars 
with diagonal line upwards) or PHA‑M (5 mg/ml, bars with spheres). 
HIV‑1 reactivation was estimated at 12 h following reactivation, by 
evaluating for GFP positive cells by flow cytometry. For comparison of 
results across samples from multiple experiments, HIV‑1 reactivation 
observed in vehicle control (DMSO) pretreatment was considered as 
100 % and the background (no reactivating agent) as 0 %. Error bars 
represent standard deviation (N = 3), *p < 0.05
◂
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latency reversal (Fig.  7a, b, e, f ). In case of TNF-α and 
PHA-M, the ability of WP1066 to block virus reactivation 
is lost by 4 and 6 h, respectively (Fig. 7c, d, g, h).
With ERK1/2 inhibitor, we observed a more gradual 
loss of inhibition over time (Fig.  7b, d, f, h) when pros-
tratin and PHA-M are included to reactivated the virus. 
The inhibition is >95 % when AZD 6244 was included 4 h 
prior to activation, this inhibition gradually decreased to 
40–60 % at 8 h post stimulation. JNK inhibitor, SP600125, 
also demonstrated consistent inhibition around 40–60 % 
with both the cell lines with all the tested reactivating 
agents but for prostratin in J-Lat TGA1cells (Fig.  7f ), 
when included 4  h prior to stimulation. This inhibi-
tory effect reduced progressively with time over to 40 % 
especially in J-Lat cell line FL10.6 (Fig. 7a–d) but did not 
change drastically till 8  h in J-Lat cell line TGA1. Rot-
tlerin showed consistent inhibition (~80–90 %) over time 
till 8 h in both the cell lines when stimulated with SAHA, 
TNF-α and PHA-M, but with prostratin, the inhibitory 
effect of rottlerin progressively reduces to ~20  % at 8  h 
post stimulation (Fig. 7b, f ). NF-κB inhibitor was able to 
consistently inhibit virus reactivation (~60–90  %) that 
remains stable over time in both the cells with all the 
tested reactivators but for in J-Lat cells TGA1 with pros-
tratin (Fig. 7f ). These results suggest that JAK-STAT has a 
role in early stage of reactivation, in the initial 2–4 h, and 
inhibiting JAK-STAT pathway after this interval does not 
inhibit latent virus reactivation with all the tested activa-
tors, though with delayed kinetics for TNF-α and PHA-
M. And this early role of JAK-STAT pathway is essential 
for viral reactivation which cannot be complemented by 
other signal or factors. With other regulatory factors like 
NF-κB, PKC, JNK and ERK1/2, the activation of these 
factors are essential at all-time points for effective reacti-
vation, though at later time points, the inhibition of these 
activated factors can complement each other, which leads 
to gradual loss of inhibitory activity.
Role of signaling pathways and regulatory networks 
in latent virus reactivation in primary T cells
Next we evaluated the role of identified signaling path-
ways and regulatory factors and the relevance of the 
two-phase reactivation process in primary resting CD4+ 
T cells. A total resting CD4+ T cell based HIV latency 
model was used to study the role of specific signaling 
pathways [30], and αCD3/αCD28 or prostratin were 
used to reactivate latent virus. Small molecule inhibi-
tors targeting ERK1/2, NF-κB, JNK, STAT and p38 were 
included either 4 h prior to stimulation or 4 h post stim-
ulation. The concentration of inhibitor, which induced 
minimal cytotoxicity (Additional file  6: Fig. S5) was 
included and were tested in triplicates in three inde-
pendent donors (Fig. 8a–d). Results confirm a consistent 
critical role for JAK-STAT and NF-κB with both αCD3/
αCD28 and prostratin in all the three donors, where 
we observed a consistent inhibition of more than 80  %. 
Overall, inhibition of virus reactivation by JNK inhibitor, 
SP600125, or ERK1/2 inhibitor AZD6244, or P38 inhibi-
tor, SB203580 were not statistically significant in rest-
ing T cells; however, JNK inhibitor, SP600125, inhibited 
virus reactivation by 40–55 % in two of the three donors 
tested with both αCD3/αCD28 and prostratin. Simi-
larly ERK1/2 inhibitor, AZD6244 had inconsistent effect 
where ~55–60  % inhibition was observed in one donor 
with both the tested reactivators. Inhibiting specific path-
ways either 4 h prior to or after addition of reactivating 
agents did not consistently alter the inhibition of virus 
reactivation. WP1066 and IΚK2 inhibitor V consist-
ently inhibited virus reactivation >80 % in all the tested 
donors (Fig. 8a–d), suggesting that JAK-STAT, NF-κB are 
required also at 4 h following stimulation with prostratin 
or αCD3/αCD28 for latent virus reactivation in primary 
T cells.
Discussion
Inability to consistently reactivate the latent viral reser-
voir is presently the main impediment in the “shock and 
kill” strategy to achieve HIV-1 cure. Numerous thera-
peutic agents and methods have been proposed to reac-
tivate the latent virus but the results vary widely between 
individual patients, suggesting that multiple factors are 
involved in determining the reactivation of latent HIV-1. 
This variability in outcomes is true for in  vitro primary 
CD4+ T cell based models as well as established T cell 
lines, where different activators are effective to reacti-
vate latent virus to variable extent. Hence there is an 
urgent need to develop innovative approaches to predict 
and identify strategies that could result in more effective 
reactivation and eventual viral elimination. Here in this 
study, using ACH-2, a T cell line (that has a single latent 
copy of replication competent provirus), we describe the 
application of a robust Systems Biology approach to pre-
dict factors that are potentially involved in latent HIV-1 
reactivation. Changes in transcripts of NT5C3 gene in 
ACH-2 cells suggest that onset of HIV latency in these 
cell lines is associated with silencing of the host gene 
where the virus integrated and can be induced upon virus 
reactivation, suggesting methods by which a retroviral 
genetic element can regulate host cellular expression. 
Additionally these changes indicate that HIV latency and 
reactivation in ACH-2 cells is associated with local chro-
mosomal changes that are specific to the region of virus 
integration, which could be due changes in the nucleoso-
mal assembly and/or DNA methylation.
Using Systems Biology method, we integrate several 
genome wide transcriptome datasets to reconstruct a 
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dynamic signaling and regulatory network for each reac-
tivating agent. This helped to specifically identify the 
critical factors for individual treatments along with their 
time of activation and the specific set of genes regulated 
by these critical factors. We validated our approach using 
specific inhibitors to confirm the cellular factors that are 
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Fig. 7 Time dependent inhibition of cellular signaling pathways in J‑Lat cells. J‑Lat FL10.6 (a–d) and J‑Lat TGA1 (e–h) cells were activated with 
SAHA (1 µM), prostratin (2 µM) or TNF‑α (0.1 ng/ml) or PHA‑M (5 μg/ml) and specific inhibitors targeting STAT, ERK1/2, PKC, NF‑κB and JNK were 
included at multiple time points, either 4 h prior to activation (white bars) or at every 2 h intervals till 8 h post activation (2 h: bars with diagonal 
downward lines; 4 h: bars with diagonal crossing lines; 6h: bars with white and black checkered pattern; 8 h: black bars). HIV reactivation was esti‑
mated at 18 h following reactivation, by evaluating for GFP positive cells by flow cytometry. For comparison of results across samples from multiple 
experiments, HIV‑1 reactivation observed in vehicle control (DMSO) pretreatment was considered as 100 % and the background (no reactivating 
agent) as 0 %. Error bars represent standard deviation (N = 3)
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critical for latent HIV-1 reactivation. The latent HIV-1 
virus in ACH-2 cells is integrated in chromosome 7 and 
has a point mutation in TAR- Tat axis C37T. It has been 
previously identified that the TAR mutation renders the 
virus less responsive to Tat and suggests that Tat-TAR 
axis may have a role in HIV-1 latency in patients [48]. 
The mutation in TAR region helps us to understand the 
cellular pathways involved in HIV-1 latency reversal in 
the early phase in the absence of viral protein Tat. Addi-
tional reports also suggest a role for DNA methylation 
in LTR region of HIV-1 virus identified in ACH-2 as the 
major contributing factor for latency and reactivation 
from latency [47]. Therefore, results from ACH-2 cells 
were further confirmed in J-Lat cell clones and primary 
T cell HIV latency model that do not contain any muta-
tions and similar results were observed, thus confirming 
the validity of the cell lines as latent cell model. SDREM 
reconstructs accurate models of the cross talk between 
signaling pathways and transcriptional regulatory 
networks within cells, which are essential to understand 
complex host cellular response programs [49]. This com-
putational method combines condition-specific time 
series expression data with general protein interaction 
data to reconstruct dynamic and causal networks [50, 
51]. Similar analyses were performed in H1N1 influenza 
infection to identify strain specific targets of Influenza 
infection [39].
Analyses of time kinetic transcriptome data corre-
sponding to the initial period of reactivation extend-
ing up to 6  h in ACH-2 cells post treatment with 
SAHA, clearly identified Jun as the key regulatory fac-
tor that is responsible for the increase in cellular tran-
scripts observed in the initial 2 h. SDREM also predicts 
NFATC1-4, CEBPE, TBP and ATF2 as potential factors 
modulating cellular transcript levels. These factors are 
known to bind to HIV-1 LTR and have a role in HIV-1 
transcription. However, interpretation of predicted fac-
tors associated with a decrease in cellular transcript level 
Fig. 8 Role of specific cellular signaling pathway in reactivation of HIV‑1 primary resting CD4+ T cells. HIV‑1 latency reversal was measured by quan‑
tification of viral RNA in the culture supernatant 7 days post‑stimulation with either αCD3/αCD28 (a, c) or Prostratin (b, d). Latently infected resting 
CD4+ T cells were treated with one of five pathway inhibitors: ERK1/2, NF‑κB, JNK, STAT and p38, for (a, b) 4 h before stimulation or (c, d) 4 h post 
stimulation. Data are normalized to virus production following stimulation with (a, c) CD3/αCD28 only or (b, d) prostratin only from three independ‑
ent experiments performed in duplicate are included. P values were determined using a paired t test. Error bars represent the standard error of the 
mean. *p < 0.05, **p < 0.005, ***p < 0.0005
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is complex, since it can mean that either association or 
dissociation of these predicted TFs may lead to sup-
pression of cellular transcripts). Some of the other top 
30 factors regulated by SAHA include—STATs, TP53, 
RB1, NF-κB related factors, BRCA1, NR3C1, CTNNB1, 
SMADs and Myc (Table 2). Though these factors are part 
of the predicted regulatory network, validating the role 
of these factors is difficult, as targeting specific cellular 
factors can result in cells using alternative compensatory 
networks, and multiple TFs can be regulated by a single 
upstream regulatory pathway, hence the recommended 
approach includes targeting specific signaling or regula-
tory pathways rather than TFs. The SDREM prediction 
for SAHA highly correlates with the results in validation 
experiments, where Jun is identified as the critical cellu-
lar factor and validation experiments using JNK inhibitor 
SP600125 inhibits SAHA induced reactivation of HIV-1 
in ACH-2 cells, and J-Lat cell lines supporting the validity 
of these analyses.
Multiple factors, including ETS1, CEBP, STATs, RELA 
and GATA 2/3, which are known to bind to HIV-1 LTR, 
are predicted by SDREM as active in ACH-2 cells within 
the initial 4  h following prostratin treatment. The pre-
dicted regulators that are unique for prostratin include 
MAPK1, SMADs2/4 and others. This prediction cor-
relates well with the results obtained in validation 
experiments, where we observed specific inhibition of 
prostratin induced HIV-1 reactivation in the presence of 
ERK1/2, NF-κB pathway and JNK inhibitors. The SDREM 
prediction is also accurate for TNF-α treatment, which 
identified NF-κB related factors, STATs, CEBP, ETS1 and 
GATA3, and the validation results correlated with the 
inhibitory effect observed with IΚK-2 inhibitor V and 
SP600125. Additionally, it can be noted that STATs are 
common in the network for all the three treatments and 
correlate with the inhibitory effect of WP1066, though 
STAT may also have a role in regulation of basal HIV-1 
LTR transcription, as we observed a decrease in p24 posi-
tive cells with WP1066 in the absence of latency reacti-
vating agents. Similar results describing a central role for 
STAT were also reported in acute HIV-1 infection and in 
reactivation of latent HIV infection by using STAT inhib-
itors Ruxolitinib and Tofacitinib [52]. Our time kinetics 
data in J-Lat cell lines further refines the role of STAT and 
restricts the requirement of JAK-STAT pathway to the 
initial immediate early stage of latent HIV reactivation. 
Other factors that are predicted in common for all three 
treatments include BRCA1, CEBPB, JUN, MYC, NR3C1, 
RELA, SMAD3, TP53 and UBC. Previous results suggest 
that Myc may have a role proviral latency by recruiting 
Histone Deacetylase 1 to the HIV-1 promoter [19], and 
we also found that c-Myc levels are reduced in the three 
treatments tested in ACH-2 cells, which may have a role 
in HIV-1 reactivation. The role of other factors identified 
as common or unique needs to be evaluated in patients.
The minor differences in degree of response and the 
cellular pathway involved are expected in different cell 
types. Previously it has been demonstrated that the latent 
HIV-1 virus in the human monocytic cell line U1 can be 
induced by cytokines, including TNF-α, which is sensi-
tive to U0126 and has been suggested to involve coop-
erative interaction of AP-1 and NF-κB at the HIV-1 LTR 
[53]. Our results though suggests that AP-1 and NF-κB 
have a critical role in TNF-α induced reactivation of 
latent virus in ACH-2 and J-Lat cells, but this does not 
require MAPK as U0126 was unable to inhibit the TNF-α 
mediated reactivation of latent HIV-1. This could be 
explained as the availability of alternate signaling path-
ways in different cell types, which might compensate for 
missing factors. Also, in the primary T cell model devel-
oped by Bosque et al. [54], it was shown that Cyclosporin 
A and p38 MAPK inhibitor inhibited αCD3/αCD28 or 
PHA-M mediated reactivation of latent HIV-1, but in 
ACH-2 cells, NFAT and p38-MAPK did not seem to have 
a role in latent HIV-1 reactivation, though NFAT seems 
to have a minor role in PHA-M induced latent virus 
reactivation in J-Lat clones. In our primary resting T cell 
model, we see a major role for JAK-STAT and NFκB in 
reversal of latency mediated by αCD3/αCD28 or pros-
tratin, with variable role for JNK and ERK1/2 which were 
found to have a minor role in some donors but not all and 
the inhibition was not statistically significant. SB203580, 
p38 MAPK inhibitor, did not show any inhibition in our 
primary T cell model, suggesting no role for p38 in latent 
virus reactivation. Similar variations were observed when 
reactivity of different in vitro primary T cell models and 
cell lines were compared [22]. SAHA was not tested in 
our primary cell model, as it is ineffective and does not 
reactivate latent HIV-1 as has been observed in in vitro 
studies using resting CD4+ T cells isolated from aviremic 
infected individuals [55–57]. Though ACH-2 cells have 
good dynamic range in their response to LRAs (Latency 
Reversing Agents), it can also be noted that the back-
ground of non-latent virus containing cells in ACH-2 
population is around ~13–20 %. This background could 
potentially undermine the magnitude of fold change 
observed in cellular transcripts induced by LRAs at the 
population level. A twofold change in transcripts in the 
75–80 % of cells will be observed as 1.5–1.6 fold change 
at the population. However, SDREM considers the 
changes observed in global transcripts over time that are 
independent of the magnitude of fold change to predict 
the upstream regulating factors, hence the reduced fold 
changes in transcripts does not affect the analyses.
Temporal inhibition of signaling pathways and regu-
latory network post activation in J-Lat cells identify a 
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biphasic mechanism where JAK-STAT pathway has an 
essential role in the initial stage and the second phase 
does not require JAK-STAT, whereas, the other signal-
ing pathways have a role. With the current results, it is 
not possible to identify if JAK-STAT acts independently 
in the initial phase or in concert with other regulatory 
molecules. Interaction of STAT with NF-κB has been 
well studied in cancer biology [58], however their role 
in HIV-1 transcriptional regulation and the mechanisms 
are unclear. Previous reports suggest that disassembly 
of nucleosome, degradation of myc are part of the early 
essential events during reactivation of latent virus, hence 
an understanding of the relationship between these 
events and JAK-STAT may help to dissect the details 
of immediate early events of reactivation. Also HIV-1 
LTR has putative sites for STAT binding and has been 
identified as essential factor for efficient LTR transacti-
vation [59], mutation of these sites may help us under-
stand if STAT has a role in early transcription initiation 
along with other known transcription factors regulating 
HIV-1 LTR activity. In summary as depicted in a sim-
plistic schematic model (Fig. 9), it is possible to predict 
that JAK-STAT either independently or in concert with 
other regulatory factors helps in the immediate early 
phase of reactivation where JAK-STAT has an essential 
role, which is followed by the next phase which, is JAK-
STAT independent phase with less fidelity in the choice 
of regulatory factors driving LTR transcription. TFs 
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that have binding sites in core, enhancer, modulatory 
or downstream TF binding region can alter the activity 
of stalled RNA polymerase at HIV-1 LTR promoter or 
aid in overcoming the reversal of inhibitory TF effects. 
Transcriptional interference has also been reported as 
one of the mechanisms contributing to HIV-1 latency, 
hence these regulatory TF activation can help to over-
come the transcriptional interference and associated 
reversal of latency.
Surprisingly, this temporal requirement of JAK-STAT 
was not observed at 4  h with prostratin or αCD3/
αCD28 in primary T cell model suggesting that the 
absence could be due to delayed kinetics of the JAK-
STAT dependent phase of virus reactivation. This is 
true in J-Lat cells when they were reactivated with 
TNF-α and PHA-M, where JAK-STAT dependent phase 
extended till 6  h post activation. Furthermore, within 
an individual, different latent reservoirs might respond 
differently based on the availability of cellular signal-
ing pathways and other factors influencing the signal 
transduction. Given the short duration time kinetics 
data required and the small amount of cells required to 
obtain transcriptome data, SDREM has potential to be 
adapted to characterize cellular signaling pathways—to 
identify defects in pathways of HIV-1 subjects, and to 
identify alternate pathways that can bypass the defects 
to reactivate the HIV-1 transcription with minimal 
adverse effects. Also, the SDREM approach will help in 
assay development—to compare functional signaling 
pathways in cell models that can closely simulate condi-
tions present in cells obtained from latent reservoir of 
HIV-1 patients.
Conclusion
Our results support the wide variations observed in out-
comes both in patients and CD4+ T cell models, sug-
gesting that cells derived from HIV-1 infected patients 
may respond differently to various activators and that 
a single strategy may not be optimal for all individuals, 
though JAK-STAT and NF-κB seems to be the common 
regulatory factors essential for latent HIV reactivation. 
JAK-STAT has an essential role in immediate early phase 
of HIV-1 latency reversal, where activation of STAT is 
critical for reversal of HIV-1 latency, though the dura-
tion of this immediate early phase varies between latent 
HIV-1 cell models tested and the LRAs used. Other cel-
lular signaling pathways including NFκB, NFAT, JNK, 
and ERK1/2 are also involved in latent HIV-1 reversal 
and could play a complement role with each other that is 
essential during reactivation. SDREM based prediction 
of cellular signaling pathways will help to optimize the 
management of HIV-1 patients to achieve the best out-
come and cure.
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chips was included (N = 2). (C) Western blot analysis of NT5C3 in ACH‑2 
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bars) or TNF‑α (0.1 ng/ml, bars with diagonal line upwards). HIV‑1 reactiva‑
tion was estimated at 12 h following treatment, by intracellular p24 Gag 
staining by flow cytometry. For comparison of results across samples from 
multiple experiments, HIV‑1 reactivation observed in vehicle control pre‑
treatment was considered as 100 % and the background (no reactivating 
agent) as 0 %. Error bars represent standard deviation (N = 3).
Additional file 5: Fig. S4: J‑Lat cells FL10.6, TGA1 and TGA2 were treated 
with multiple doses of (A) Rottlerin and (B) WP1066 or vehicle control 
(DMSO), and 16 h post‑treatment, the live cells were evaluated by Trypan 
blue staining. The percentage of viable cells was calculated by subtract‑
ing the dead cells from total cells divided by total cell count. Viability of 
cells in the vehicle control was considered as 100 % for comparison across 
three independent experiments. Error bars represent standard deviation 
(N = 3).
Additional file 6: Fig. S5. Primary resting CD4+ T cells were treated 
with multiple concentrations of small molecules inhibiting specific 
cellular signaling pathway. Cell viability was evaluated after 3 days by 
flow cytometry and trypan blue staining. Results from two independent 
donors tested in duplicates that are normalized to DMSO only control are 
included.
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